Cytodyn (or actually Amarex as the CRO) would set the values it thinks would be a high enough efficacy that it would be best to halt the trial and submit. The DSMC takes everything into consideration when making their recommendations and don't totally rely on preliminary values. In rare circumstances the DSMC could also determine that the p values aren't in line with other outcomes of the trial and could recommend something other than what is outlined by the preliminary DSMC plan.